French drugmaker Sanofi said on Tuesday that its Zaltrap drug had been approved for marketing in the European Union to treat advanced bowel cancer.


The approval follows a recommendation from the European Medicines Agency in November based on a late-stage study of the drug that showed significant improvement in survival among patients with colon cancer.